Verify patient identity, confirm absence of active infections, review coagulation profile and platelet count, obtain written informed consent, administer local anesthetic at the access site, and ensure standard antiplatelet therapy protocol.
Monitor vital signs and puncture site for hematoma for 2-4 hours, ensure patient can ambulate, confirm stability of peripheral pulses, provide discharge instructions regarding antiplatelet medication adherence and wound care, and ensure patient is cleared for same-day discharge.
Comprehensive Clinical Guide: Percutaneous Coronary Intervention (PCI) with Bare Metal Stent (BMS)
1. Introduction & Overview
Percutaneous Coronary Intervention (PCI), historically known as coronary angioplasty, remains the cornerstone of interventional cardiology for the management of obstructive coronary artery disease (CAD). While the landscape of coronary intervention has shifted significantly toward Drug-Eluting Stents (DES), the Bare Metal Stent (BMS) retains a critical, albeit niche, position in the clinical armamentarium.
A Bare Metal Stent is a fine, mesh-like scaffold constructed from medical-grade metal alloys—typically stainless steel or cobalt-chromium—designed to act as a permanent internal splint for a coronary artery. Unlike DES, BMS lacks a polymer coating and a pharmacologic agent intended to inhibit neointimal hyperplasia. This guide provides an exhaustive clinical overview of the BMS, its mechanism, procedural application, and its evolving role in modern cardiology.
2. Technical Specifications & Mechanisms
The primary mechanical objective of a BMS is to prevent "recoil"—the elastic contraction of the vessel wall post-balloon angioplasty—and to prevent "flow-limiting dissection" or intimal flaps that can lead to acute vessel closure.
Material Science and Design
- Structural Composition: Modern BMS are generally laser-cut from high-strength alloys. Cobalt-chromium is favored for its high radial strength, allowing for thinner struts compared to traditional stainless steel.
- Strut Thickness: Thinner struts (typically <100 µm) are associated with improved deliverability and lower rates of restenosis due to reduced injury to the vessel wall and faster endothelialization.
- Expansion Mechanism: The stent is mounted on a semi-compliant or non-compliant balloon catheter. Upon inflation, the stent undergoes plastic deformation, locking into the vessel wall.
The Mechanism of Action
- Mechanical Scaffolding: Provides immediate structural support to the lumen.
- Endothelialization: Because there is no drug to inhibit cell growth, the BMS is covered by a layer of endothelial cells relatively quickly (usually within 4–8 weeks), theoretically reducing the duration of mandatory dual antiplatelet therapy (DAPT) compared to DES.
3. Extensive Clinical Indications & Usage
While DES is the default choice for most patients, BMS is specifically indicated in scenarios where long-term DAPT is contraindicated or impossible to maintain.
| Clinical Scenario | Rationale for BMS Usage |
|---|---|
| High Bleeding Risk (HBR) | Patients unable to tolerate long-term DAPT (e.g., history of intracranial hemorrhage, active GI bleed). |
| Urgent Non-Cardiac Surgery | Patients requiring imminent surgery where DAPT must be discontinued prematurely. |
| Small Vessel Disease | Occasionally used in very specific distal vessels where stent size limitations apply. |
| Patient Non-compliance | Scenarios where the patient is unlikely to adhere to complex medication regimens. |
| Known Drug/Polymer Allergy | Rare cases of hypersensitivity to DES polymers or specific antiproliferative drugs. |
4. Pre-Operative Preparation
Preparation for PCI is a multidisciplinary process involving the interventional cardiologist, nursing staff, and the patient.
- Laboratory Assessment: CBC, coagulation profile (PT/INR/PTT), serum creatinine (to assess renal risk due to contrast), and cardiac biomarkers (troponins).
- Medication Optimization:
- Loading Doses: Administration of aspirin (325mg) and a P2Y12 inhibitor (Clopidogrel, Ticagrelor, or Prasugrel) prior to the procedure.
- Anticoagulation: Initiation of heparin or bivalirudin in the catheterization lab.
- Patient Education: Informed consent, discussing the risks of bleeding, contrast-induced nephropathy, and the necessity of post-procedure medication adherence.
5. Procedural Steps: The Intervention
The PCI procedure is performed in a sterile cardiac catheterization laboratory under fluoroscopic guidance.
- Access: Percutaneous access is obtained via the radial artery (preferred for lower complication rates) or the femoral artery.
- Angiography: Selective cannulation of the coronary ostia with guiding catheters, followed by contrast injection to map the anatomy.
- Lesion Crossing: A 0.014-inch coronary guidewire is advanced across the target stenosis.
- Predilatation: A balloon catheter is inflated at the lesion site to prepare the vessel for the stent.
- Stent Deployment: The BMS is positioned over the lesion and deployed by inflating the balloon to the manufacturer’s specified nominal pressure.
- Post-Dilatation: A non-compliant balloon is often used to ensure full stent apposition against the vessel wall.
- Final Imaging: Follow-up angiography ensures optimal flow and absence of residual dissection or complications.
6. Post-Operative Recovery Protocol
Recovery focuses on hemodynamic stabilization and the mitigation of bleeding risks at the access site.
- Immediate Post-Op: Monitoring of vital signs and distal pulses (pedal or radial) every 15–30 minutes.
- Access Site Management: Hemostasis via compression devices (e.g., TR Band for radial access) or vascular closure devices (e.g., Angio-Seal).
- Medication Management: Continuation of DAPT. For BMS, DAPT is typically required for a minimum of 1 month, though 3–6 months is often preferred depending on clinical context.
- Activity: Usually restricted for 24–48 hours; progressive return to normal activities within one week.
7. Risks, Complications, and Contraindications
Potential Complications
- In-Stent Restenosis (ISR): The most significant drawback of BMS. The lack of antiproliferative drugs leads to neointimal hyperplasia, which can narrow the stent lumen.
- Stent Thrombosis: Acute or subacute occlusion due to incomplete endothelialization or discontinuation of DAPT.
- Vascular Injury: Dissection, perforation, or hematoma at the access site.
- Contrast-Induced Nephropathy (CIN): Particularly in patients with pre-existing renal insufficiency.
Contraindications
- Severe Bleeding Diathesis: Where any anticoagulant/antiplatelet therapy is hazardous.
- Vessel Anatomy: Extremely tortuous or calcified vessels that cannot accommodate the stent delivery system.
- In-Stent Restenosis: BMS is rarely the primary choice for treating existing ISR.
8. Alternative Treatments
- Drug-Eluting Stents (DES): The current standard of care for most patients, significantly reducing the rate of ISR.
- Coronary Artery Bypass Grafting (CABG): Preferred for left main disease, complex multivessel disease, and diabetes with high SYNTAX scores.
- Balloon Angioplasty (POBA): Rarely used alone today, reserved for very small vessels or when stenting is not anatomically feasible.
- Medical Management: Optimized Guideline-Directed Medical Therapy (GDMT) for stable CAD without high-risk features.
9. Massive FAQ Section
Q1: Is a Bare Metal Stent better than a Drug-Eluting Stent?
A: Generally, no. DES are superior in reducing the risk of restenosis. BMS is reserved for specific patients who cannot tolerate long-term blood-thinning medication.
Q2: How long does a BMS stay in the body?
A: It is a permanent implant and remains in the coronary artery for the patient's lifetime.
Q3: What is "In-Stent Restenosis"?
A: It is the re-narrowing of the stented segment, usually caused by the overgrowth of smooth muscle cells (neointimal hyperplasia). It is more common in BMS than in DES.
Q4: Can I undergo an MRI with a BMS?
A: Yes. Most modern coronary stents are MRI-conditional. However, always inform the radiology staff of the stent's presence.
Q5: What happens if I stop taking my antiplatelet medication?
A: Stopping medication prematurely significantly increases the risk of stent thrombosis, which can lead to a sudden, life-threatening myocardial infarction (heart attack).
Q6: How is a BMS different from a "Bioabsorbable Scaffold"?
A: A BMS is a permanent metal structure. A bioabsorbable scaffold is designed to disappear over time, leaving only the natural vessel behind.
Q7: Does a stent cure coronary artery disease?
A: No. A stent treats the symptoms of a specific blockage. The underlying disease (atherosclerosis) requires ongoing management through diet, exercise, and lipid-lowering therapy (statins).
Q8: What are the warning signs of a complication?
A: Sudden chest pain, shortness of breath, or dizziness after discharge should be treated as a medical emergency.
Q9: How long does the actual PCI procedure take?
A: Uncomplicated cases typically last 30 to 90 minutes, though complex cases may take longer.
Q10: Can I have a stent if I am allergic to nickel?
A: Many stents contain nickel. If a known severe allergy exists, the interventional cardiologist must be informed to select an alternative device or plan for prophylactic management.
10. Clinical Summary Table: BMS vs. DES
| Feature | Bare Metal Stent (BMS) | Drug-Eluting Stent (DES) |
|---|---|---|
| Restenosis Risk | Higher | Lower |
| DAPT Duration | Short (1–3 months) | Long (6–12+ months) |
| Endothelialization | Faster | Slower |
| Primary Indication | High Bleeding Risk | Standard CAD/PCI |
| Cost | Generally lower | Generally higher |
11. Conclusion
The Bare Metal Stent remains a vital tool in the interventional cardiologist’s toolkit. While the clinical focus has shifted to the superior outcomes provided by DES in the general population, the BMS provides a necessary solution for patients with contraindications to prolonged DAPT. Mastery of the indications, procedural nuances, and post-operative management of BMS ensures that clinicians can provide personalized, safe, and effective care for the most challenging patient presentations. Patients should maintain open communication with their cardiology team regarding their specific anatomy, risk profile, and medication regimen to ensure the best long-term prognosis.